+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

STD Testing - Global Strategic Business Report

  • PDF Icon

    Report

  • 197 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5141566
The global market for STD Testing was estimated at US$101.9 Billion in 2023 and is projected to reach US$144.8 Billion by 2030, growing at a CAGR of 5.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global STD Testing Market - Key Trends & Drivers Summarized

Why Is STD Testing Gaining Urgency and Attention Worldwide?

The rising prevalence of sexually transmitted diseases (STDs) across the globe has led to a significant increase in demand for STD testing services. Factors such as changing sexual behavior, lack of awareness, and inadequate education on safe practices have contributed to the surge in STD cases. In response, healthcare organizations and governments are promoting early diagnosis and routine testing to curb the spread of infections and improve patient outcomes. The expansion of public health campaigns and increased access to healthcare services, particularly in developing regions, are also contributing to the emphasis on STD testing. With diseases like HIV, chlamydia, gonorrhea, and syphilis being major public health concerns, the importance of accessible, reliable, and rapid testing solutions continues to grow, underscoring the urgent need for comprehensive testing programs worldwide.

How Are Technological Advancements Influencing the STD Testing Landscape?

The STD testing market is being reshaped by technological advancements aimed at improving diagnostic speed, accuracy, and accessibility. Point-of-care (POC) testing devices are becoming increasingly popular, offering rapid results without the need for laboratory processing, which is essential for early intervention and treatment. Molecular diagnostics, such as polymerase chain reaction (PCR) tests, are enhancing the precision of STD detection, allowing for the identification of multiple pathogens from a single sample. Self-testing kits, which can be used privately at home, are also gaining traction as they provide a convenient and discreet way for individuals to manage their sexual health. The integration of mobile health (mHealth) platforms that connect users with healthcare professionals for remote consultations and result interpretation is further enhancing the reach and efficiency of STD testing services, especially in remote or underserved areas.

What Are the Market Trends Influencing the Demand for STD Testing Services?

The increasing awareness of sexual health and the rising prevalence of STDs, particularly among the younger population, are significantly influencing the demand for STD testing services. Educational campaigns and public health initiatives, particularly those targeting at-risk groups like young adults, LGBTQ+ communities, and sex workers, are emphasizing the importance of regular testing and early diagnosis. The shift towards preventive healthcare and personalized medicine is also playing a role, as healthcare providers advocate for proactive screening and routine check-ups to mitigate the spread of infections. Additionally, the expansion of telemedicine services, which offer convenient access to STD testing and consultations, is making testing more accessible and appealing, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of remote healthcare solutions. These trends indicate a growing acceptance and demand for routine STD testing as part of comprehensive healthcare management.

What Factors Are Driving the Growth of the STD Testing Market?

The growth in the STD testing market is driven by several factors, including the rising prevalence of STDs, technological advancements in diagnostic tools, and the increasing emphasis on preventive healthcare. The expansion of point-of-care testing technologies and the availability of at-home testing kits are making testing more accessible, particularly for individuals who prefer privacy and convenience. The integration of molecular diagnostics, which enhances the accuracy and speed of test results, is attracting healthcare providers looking for efficient ways to manage and prevent the spread of infections. Public health initiatives and educational campaigns are also expanding testing access, particularly in developing regions where healthcare infrastructure is improving. Additionally, the widespread adoption of telemedicine services is facilitating remote consultations and access to testing, further supporting market growth. These combined factors are propelling the expansion of the STD testing market, making it a critical component of modern healthcare.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Chlamydia Testing segment, which is expected to reach US$40.6 Billion by 2030 with a CAGR of a 5.0%. The Herpes Simplex Virus Testing segment is also set to grow at 6.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $27.3 Billion in 2023, and China, forecasted to grow at an impressive 8.2% CAGR to reach $31.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global STD Testing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global STD Testing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global STD Testing Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Global STD Testing Market such as Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 47 companies featured in this Global STD Testing market report include:

  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession
  • STD Testing - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Sexually Transmitted Diseases (STDs) Worldwide
  • Increasing Demand for Rapid and Point-of-Care Testing Solutions
  • Growth in Awareness Campaigns Promoting Routine STD Testing
  • Expansion of At-Home Testing Kits for Privacy and Convenience
  • Surge in Telemedicine Services Facilitating Remote STD Testing
  • Technological Advancements in Multiplex and PCR-Based Tests
  • Growing Focus on Early Detection and Preventive Healthcare
  • Rising Use of Mobile Health (mHealth) Apps for Test Scheduling and Results
  • Development of Combination Test Kits Covering Multiple STDs
  • Increasing Availability of Affordable STD Testing Solutions in Emerging Markets
  • Growth in Use of Self-Collection Kits for Enhanced Patient Comfort
  • Rising Collaboration Between Public Health Organizations and Testing Providers
  • Expansion of Laboratory Infrastructure Supporting High-Volume Testing
  • Surge in Demand for Digital Platforms Offering Confidential STD Testing
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World STD Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Human Papillomavirus (HPV) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Laboratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Point-of-Care (POC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Canada Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Canada 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
JAPAN
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Japan Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Japan 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
CHINA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 47: China Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: China Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: China 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
EUROPE
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
FRANCE
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 62: France Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: France Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: France 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
GERMANY
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Germany Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Germany 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Italy Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Italy 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: UK Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: UK 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
SPAIN
  • Table 86: Spain Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Spain Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Spain 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 89: Spain Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Spain Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Spain 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
RUSSIA
  • Table 92: Russia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Russia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Russia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 95: Russia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Russia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Russia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Rest of Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: Rest of Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 112: Asia-Pacific 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
AUSTRALIA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

Some of the 47 companies featured in this Global STD Testing market report include:
  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

Table Information